Gilead's Biktarvy Patent Extended to 2036
Gilead Sciences settled lawsuits with generic manufacturers, securing market exclusivity for Biktarvy until April 2036.
Already have an account? Sign in.
Gilead Sciences settled lawsuits with generic manufacturers, securing market exclusivity for Biktarvy until April 2036.
Eli Lilly raised profit outlook thanks to strong Zepbound & Mounjaro sales; revenue and earnings beat expectations, stock rose.
Samsung hit record profit from AI chip demand. Memory shortages raised prices, while phone/display profits fell.
Ford raised 2026 profit outlook after strong Q1, boosted by higher sales, tariff refund, and growth in trucks and software.